Bulk Pharmaceutical API Sources for OPTISON

Bulk Pharmaceutical API Sources for OPTISON

Vendor	Vendor Homepage	Vendor Sku	API Url
Amadis Chemical		A838638
AKos Consulting & Solutions		AKOS006228213
TimTec		SBB090673
Debye Scientific Co., Ltd		DB-056033
abcr GmbH		AB104454
Finetech Industry Limited		FT-0621948

Bulk Active Pharmaceutical Ingredient (API) Sources for OPTISON

Last updated: February 19, 2026

This analysis identifies and evaluates potential bulk active pharmaceutical ingredient (API) sources for OPTISON (perflutren lipid microsphere). OPTISON is an ultrasound contrast agent approved by the U.S. Food and Drug Administration (FDA) for intravenous use to opacify the left ventricular chamber and visualize the endocardium in patients with suspected or known left ventricular systolic dysfunction [1]. The API consists of perflutren (a gas, C3F8) encapsulated within a lipid microsphere formulation. Sourcing challenges for such a specialized API are significant, requiring expertise in fluorocarbon synthesis and sterile manufacturing.

What is the Primary Active Pharmaceutical Ingredient (API) for OPTISON?

The primary API for OPTISON is perflutren, a perfluorocarbon gas [1]. Perflutren is a fluorinated alkane with the chemical formula C3F8. It is a non-ionic, lipophobic, and hydrophobic gas that is biologically inert and does not undergo metabolic transformation in the body [2]. For its use in OPTISON, perflutren is encapsulated within a lipid microsphere formulation, creating stable microbubbles that serve as the ultrasound contrast agent [1]. The lipid shell is composed of a mixture of phospholipids: dipalmitoylphosphatidylcholine (DPPC), disteroylphosphatidylglycerol (DSPG), and cholesterol [2].

What are the Key Manufacturing Challenges for Perflutren API?

The manufacturing of perflutren API presents several technical hurdles:

• Fluorocarbon Synthesis: Perfluorocarbons, including perflutren, are synthesized through electrochemical fluorination (ECF) or direct fluorination processes. These methods require specialized equipment, high energy input, and rigorous safety protocols due to the highly reactive nature of fluorine. ECF typically involves passing an electric current through a solution of the organic precursor in anhydrous hydrogen fluoride (HF). Direct fluorination uses elemental fluorine gas (F2) to replace hydrogen atoms with fluorine. Both processes can yield complex mixtures requiring extensive purification to isolate the desired perflutren.
• Purity and Isomer Control: Achieving high purity of perflutren is critical. Impurities can affect gas stability, microsphere formation, and potentially introduce toxicity. The synthesis can produce various isomers or byproducts that need to be separated.
• Sterile Manufacturing: As an injectable pharmaceutical, the perflutren gas and the lipid components must be manufactured under aseptic conditions. This involves stringent environmental controls, validated sterilization processes for all materials and equipment, and meticulous handling to prevent microbial contamination.
• Lipid Component Sourcing and Quality: The phospholipids and cholesterol used for the microsphere shell must meet pharmaceutical-grade specifications. Their quality, including purity, fatty acid chain length, and stereochemistry, directly impacts the stability and performance of the final OPTISON product. Sourcing these specific, high-purity lipids from reliable suppliers is essential.
• Microsphere Encapsulation: The process of encapsulating the perflutren gas within the lipid microsphere is a complex physical process. Maintaining precise control over particle size distribution, shell integrity, and gas content within the microspheres is paramount for consistent product performance and safety. This often involves sonication, emulsification, or other methods under controlled conditions.
• Regulatory Compliance: Manufacturing facilities and processes must adhere to current Good Manufacturing Practices (cGMP) as defined by regulatory agencies like the FDA and EMA. This includes comprehensive documentation, validation of all processes, and robust quality control measures.

Who are the Potential Suppliers of Perflutren Gas?

Direct suppliers of pharmaceutical-grade perflutren gas are limited due to the specialized nature of fluorocarbon chemistry and the stringent regulatory requirements for API manufacturing. Typically, API production for such niche products is either handled in-house by the innovator company or contracted to highly specialized contract manufacturing organizations (CMOs) with proven expertise in fluorochemicals and sterile API synthesis.

Primary Manufacturing Entity: Bracco Diagnostics Inc. (formerly part of Bristol-Myers Squibb, which originally developed OPTISON) is the primary entity involved in the manufacturing and supply of OPTISON. While they may utilize specialized chemical suppliers for precursor materials, the final perflutren gas and the finished product are likely manufactured under their direct control or via tightly managed CMOs [3].

Potential Specialized CMOs with Relevant Capabilities: Identifying publicly listed CMOs with direct experience in pharmaceutical-grade perflutren gas manufacturing is challenging. However, companies with broad capabilities in fluorochemical synthesis and sterile API manufacturing might be considered for contract development and manufacturing. These include:

• Fluorochem Inc.: Specializes in fluorinated compounds, though primarily for research and industrial applications. Pharmaceutical-grade manufacturing would require significant process validation and regulatory investment.
• Thermo Fisher Scientific (Specialty Gases Division): While known for a wide range of gases, their pharmaceutical API manufacturing arm would need to demonstrate specific expertise in perfluorocarbon synthesis and sterile encapsulation.
• Companies specializing in inhaled drugs or sterile injectable APIs: CMOs with expertise in sterile product manufacturing, lyophilization, and handling of gaseous APIs could potentially adapt their facilities and processes. Examples include:
  • Catalent: Offers broad pharmaceutical development and manufacturing services, including sterile injectables and complex APIs.
  • Lonza: A major player in custom API manufacturing, with significant expertise in sterile drug product manufacturing.

It is highly unlikely that a readily available "off-the-shelf" pharmaceutical-grade perflutren API is available from multiple independent suppliers. The complexity and proprietary nature of the manufacturing process for contrast agents like OPTISON mean that supply chains are typically tightly controlled.

What are the Sourcing Considerations for Lipid Components?

The lipid components of OPTISON, including dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylglycerol (DSPG), and cholesterol, are critical for the formation and stability of the lipid microspheres. Sourcing these materials requires a focus on pharmaceutical-grade quality and consistent supply.

Key Lipid Components:

• Dipalmitoylphosphatidylcholine (DPPC): A saturated phospholipid.
• Disteroylphosphatidylglycerol (DSPG): A saturated phospholipid, anionic.
• Cholesterol: A sterol lipid.

Sourcing Considerations:

• Pharmaceutical Grade: Materials must meet stringent purity standards as defined by pharmacopoeias (e.g., USP, Ph. Eur.) or equivalent internal specifications. This includes limits on related substances, residual solvents, and heavy metals.
• Chirality and Isomer Purity: For phospholipids, ensuring the correct stereochemistry and freedom from unwanted isomers is important for predictable physical properties and biological interactions.
• Fatty Acid Saturation and Chain Length: The precise saturation and chain length of the fatty acids (e.g., palmitoyl for DPPC, stearoyl for DSPG) are integral to the membrane properties of the microsphere, influencing its rigidity and stability.
• Supplier Qualification: Rigorous supplier qualification processes are necessary, including audits of manufacturing facilities, quality management systems, and change control procedures.
• Supply Chain Security: Ensuring a stable and uninterrupted supply of these specialized lipids is vital. Dual sourcing or strong relationships with key suppliers are advisable.
• Custom Synthesis vs. Commercial Availability: While DPPC and cholesterol are more common lipids and may be available from several suppliers, DSPG might be more specialized. Pharmaceutical-grade DSPG may require custom synthesis or sourcing from manufacturers with specific expertise in phospholipid production for pharmaceutical applications.

Potential Suppliers for Lipid Components:

Several companies specialize in high-purity lipids for pharmaceutical use. These suppliers typically offer lipids that meet cGMP requirements.

• Croda Healthcare: A leading supplier of excipients, including a range of phospholipids and cholesterol, often with cGMP compliance and pharmaceutical-grade specifications. They offer lipids like DPPC and cholesterol.
• Avanti Polar Lipids, Inc.: A well-known producer of high-purity lipids for research and pharmaceutical applications. They offer a comprehensive catalog of phospholipids and sterols, including DPPC and DSPG, with various purity grades available.
• Lipoid GmbH: Specializes in the production of natural and synthetic phospholipids for pharmaceutical applications, including those used in liposomes and lipid nanoparticles. They can provide cGMP-compliant DPPC and potentially DSPG.
• NOF Corporation (Specialty Chemicals): Offers a range of functional chemicals, including phospholipids for pharmaceutical applications.

The selection of lipid suppliers would depend on their ability to consistently produce DSPG and DPPC to the exact specifications required for OPTISON, including particle morphology and purity, and their compliance with pharmaceutical cGMP.

What is the Regulatory Landscape for OPTISON API?

The regulatory landscape for APIs used in injectable contrast agents like OPTISON is highly stringent, driven by patient safety requirements.

• Drug Master Files (DMFs): API manufacturers typically file Drug Master Files (DMFs) with regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These confidential documents contain detailed information about the API's manufacturing process, quality control, stability, and specifications. The drug product applicant (e.g., Bracco Diagnostics) cross-references the relevant DMF in their New Drug Application (NDA) or Marketing Authorization Application (MAA).
• cGMP Compliance: Manufacturing facilities for both the perflutren gas and the lipid components must be in full compliance with current Good Manufacturing Practices (cGMP). Regulatory agencies conduct regular inspections to ensure adherence. For perflutren, the sterile processing aspect is particularly critical.
• Specifications and Testing: Robust specifications must be established for the perflutren API and each lipid component, including identity, purity, assay, impurity profiles, particle size distribution (for lipids if applicable to their form), and sterility. Validated analytical methods are required for all testing.
• Stability Studies: Comprehensive stability studies under various storage conditions are necessary to establish retest dates or expiry dates for the API.
• Change Control: Any changes to the manufacturing process, raw materials, analytical methods, or facilities must be managed through a strict change control system and may require regulatory notification or approval depending on the significance of the change.
• Impurity Profiling: Identification and qualification of all impurities above certain thresholds are mandated. For perfluorocarbons, potential impurities might include incompletely fluorinated precursors or other fluorinated byproducts.
• Sterility Assurance: For the perflutren gas and its immediate handling prior to encapsulation, and for the final product, sterility is a critical attribute that requires validated sterilization methods (e.g., filtration for liquids, terminal sterilization for final product if feasible, or aseptic processing) and robust environmental monitoring programs.

The innovator company, Bracco Diagnostics, would hold the primary regulatory responsibility for the drug product (OPTISON). They would audit and qualify their API suppliers, ensuring that the suppliers' DMFs and manufacturing processes meet all regulatory requirements.

What are the Potential Business and Investment Implications?

The sourcing of bulk API for OPTISON presents specific business and investment considerations:

• High Barriers to Entry: The specialized nature of perfluorocarbon synthesis and sterile API manufacturing creates significant barriers to entry for new API suppliers. This reduces competitive pressure but also limits potential sourcing options for the drug product manufacturer.
• Proprietary Manufacturing Processes: The precise manufacturing processes for perflutren gas and its encapsulation are likely proprietary to the innovator or their contracted CMO. This proprietary knowledge is a key asset and a significant factor in supply chain stability.
• Limited Supplier Pool: The number of qualified suppliers for pharmaceutical-grade perflutren gas is likely very small, potentially only one or two specialized CMOs with unique capabilities. For lipid components, while the pool is larger, finding suppliers capable of meeting the exact pharmaceutical-grade specifications for all three components consistently is key.
• Supply Chain Risk: Reliance on a limited number of specialized suppliers increases supply chain risk. Any disruption at a key supplier (e.g., due to a quality issue, regulatory action, or geopolitical event) could significantly impact the availability of OPTISON.
• Cost of Goods: The complex synthesis and manufacturing processes contribute to a higher cost of goods for OPTISON compared to simpler APIs. This cost is a significant factor in pricing and profitability.
• Investment Opportunities:
  • Specialized CMOs: Investment in CMOs that possess unique capabilities in fluorochemical synthesis and sterile API manufacturing could be attractive. Demonstrating a track record with complex gases or sterile products would be a prerequisite.
  • Lipid Manufacturers: Investment in companies that can reliably produce high-purity, pharmaceutical-grade phospholipids (especially DSPG) and cholesterol to stringent specifications could be an avenue.
  • Technology Development: Innovation in more efficient or environmentally friendly perfluorocarbon synthesis or novel encapsulation techniques could present opportunities.
• Intellectual Property: The patent landscape surrounding the manufacturing process for OPTISON and its API is crucial. Expired patents may open opportunities for generic competition, but process patents can extend exclusivity. Understanding the IP status of specific manufacturing routes is vital.

The current patent expiry status for OPTISON's core composition of matter patents would dictate the opportunity for generic development. However, even with patent expiry, the technical challenges in API manufacturing would remain a significant hurdle for generic entrants.

Key Takeaways

• The API for OPTISON is perflutren gas, a specialized perfluorocarbon, encapsulated in lipid microspheres.
• Manufacturing challenges include complex fluorocarbon synthesis, sterile processing, and precise lipid encapsulation.
• The direct supplier pool for pharmaceutical-grade perflutren gas is extremely limited, likely involving specialized CMOs or in-house manufacturing by the innovator.
• Sourcing pharmaceutical-grade phospholipids (DPPC, DSPG) and cholesterol requires qualified suppliers with stringent quality controls.
• Regulatory compliance, particularly cGMP and sterile manufacturing standards, is paramount.
• High barriers to entry, limited supplier options, and significant supply chain risk characterize the API sourcing landscape for OPTISON.

Frequently Asked Questions

1. Can perflutren gas be synthesized using standard chemical processes? No, perflutren synthesis requires specialized techniques like electrochemical fluorination or direct fluorination, involving highly reactive and hazardous materials like anhydrous hydrogen fluoride and elemental fluorine gas. These processes demand specialized equipment and stringent safety protocols not found in standard chemical synthesis.

2. Are there generic versions of OPTISON available, and if so, how does API sourcing differ? As of late 2023, a quick search of FDA Orange Book does not immediately reveal approved generic versions of OPTISON. The development of generics is highly dependent on patent expiry and the ability of other manufacturers to replicate the complex API manufacturing and formulation processes. If generics were to emerge, they would need to identify and qualify their own suppliers of perflutren and the lipid components, facing the same significant technical and regulatory hurdles.

3. What are the key quality control parameters for perflutren API? Key quality control parameters include identity verification, assay (purity), limits for specific process-related impurities and degradation products, moisture content, and sterility. For the perflutren gas, ensuring the absence of other gases or volatile organic compounds is crucial.

4. How does the lipid composition of OPTISON's microspheres affect its performance? The specific combination of DPPC, DSPG, and cholesterol creates a rigid yet flexible lipid shell. DPPC and DSPG provide structural integrity and control the membrane fluidity, while cholesterol modulates membrane rigidity and stability. This precise composition ensures the formation of stable microbubbles of a controlled size, which are essential for effective ultrasound scattering and longevity in circulation, thereby optimizing contrast enhancement.

5. What are the risks associated with using non-pharmaceutical-grade lipids for OPTISON formulation? Using non-pharmaceutical-grade lipids would introduce significant risks. These lipids may contain impurities, varying fatty acid compositions, or incorrect stereochemistry, leading to inconsistent microsphere formation, altered stability, reduced echogenicity, increased immunogenicity, and potentially adverse patient reactions. Regulatory agencies require that all components of injectable drugs meet pharmaceutical-grade standards.

Citations

[1] Bracco Diagnostics Inc. (n.d.). OPTISON® (perflutren lipid microspheres) injectable suspension. Retrieved from [Bracco Diagnostics website or prescribing information] (Note: Specific URL for prescribing information would be inserted here if directly accessed).

[2] J. M. Rosenfield, et al. (2007). Echocardiographic contrast agents. European Journal of Echocardiography, 8(6), 451-461. doi: 10.1016/j.ejechocard.2007.07.002

[3] U.S. Food & Drug Administration. (2022). Drugs@FDA. Retrieved from [FDA Drugs@FDA database for OPTISON approval information] (Note: Specific NDA or approval information would be cited here).